This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Emerging Treatments in Schizophrenia Video

Experts discuss the brain circuits involved in schizophrenia, the current medications, and new agents in phase 3 trials that do not directly block postsynaptic D2 receptors. Phase 2 data on one of these agents, the TAAR1 agonist ulotaront, are summarized.

Read the InfoPack

Quick Links: Psychopharmacology , Schizophrenia and Schizoaffective Disorders


Sign-up to stay
up-to-date today!


Already registered? Sign In

Brief Report

Factors Associated With Remission of Suicidal Ideation During the COVID-19 Pandemic: A Population-Based, Longitudinal Study in US Military Veterans

This study compared veterans with and without remission of suicidal ideation during the pandemic on pre- and...